Inflammatory cells remain in blood after treatment of severe asthma, suggests research Dr. Kamal Kant Kohli11 July 2025 8:15 AM ISTBiological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet in Sweden shows that some...
Medical Bulletin 01/Jul/2025 Dr. Bhumika Maikhuri1 July 2025 3:00 PM ISTHere are the top medical news for the day:Why Asthma Often Comes Back After Stopping Biologic Drugs?While biological drugs have significantly improved...
Why Asthma Often Comes Back After Stopping Biologic Drugs? Study Sheds Light Dr. Bhumika Maikhuri1 July 2025 8:00 AM ISTWhile biological drugs have significantly improved the quality of life for individuals with severe asthma, a new study from the Karolinska Institutet...
FDA Approves Mepolizumab for Eosinophilic COPD Dr. Kamal Kant Kohli25 May 2025 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in...
GSK Nucala wins USFDA OK for use in adults with COPD Ruchika Sharma23 May 2025 12:17 PM ISTLondon: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on maintenance treatment for...
GSK application to expand use of Nucala for COPD accepted for review by EMA Ruchika Sharma25 March 2025 1:30 PM ISTIL-5 is a key cytokine (protein) in type 2 inflammation which is an underlying driver in many diseases.
GSK Nucala application for COPD accepted for review in China Ruchika Sharma23 Feb 2025 12:30 PM ISTGSK plc has announced that the China National Medical Products Administration has accepted for review the new drug application for the use of...
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma4 Jan 2025 1:00 PM ISTLondon: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody...
USFDA accepts GSK submission for use of Nucala in COPD Ruchika Sharma11 Dec 2024 11:30 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the...
GSK announces positive results from phase III trial of Nucala in COPD Ruchika Sharma8 Sept 2024 1:30 PM ISTLondon: GSK plc has announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) a...
GSK Nucala approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma3 Sept 2024 4:19 PM ISTGSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Nucala (mepolizumab), a monoclonal antibody that...
Submit details of adverse events reported: CDSCO Panel Tells GSK on Mepolizumab Powder for Solution for Injection Dr. Divya Colin24 Aug 2024 6:00 PM ISTNew Delhi: In line with the Phase IV clinical trial report of the monoclonal antibody Mepolizumab (Brand Name: Nucala 100 mg) presented by the drug...
